Benzothiazole Compounds as SUMO Activators for SERCA2a Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for heart failure, cancer, neurodegenerative disorders, viral and bacterial infections, liver disease, and inflammation lack effective small molecules that enhance SERCA2a SUMOylation, a crucial post-translational modification for improving cardiac function and treating various diseases.
Innovation Solution
Development of compounds of Formula I and Formula II, which are administered to patients to activate SUMO1 and increase SERCA2a SUMOylation, thereby treating heart failure, cardiac hypertrophy, myocarditis, myocardial infarction, ischemia, cardiac arrhythmias, and other conditions by enhancing the stability and ATPase activity of SERCA2a.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SUMO1 levels are increased through gene delivery, then SERCA2a stability and ATPase activity are improved, but device complexity and treatment invasiveness increase
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that activate the endogenous SUMO1 pathway. These compounds bind to and activate SUMO1 or components of the SUMOylation machinery, thereby increasing SERCA2a SUMOylation without requiring direct gene delivery. This mediator approach bridges the gap between simple administration and effective SUMO1 restoration.
Solution Approach 2:
The patent replaces the mechanical/gene delivery system (AAV-mediated gene transfer) with a chemical system (small molecule compounds). Instead of introducing foreign genetic material that requires complex delivery mechanisms, the invention uses orally administrable compounds that chemically activate the existing SUMO1 pathway, substituting a simpler chemical approach for a complex biological delivery system.
2Productivity
If SUMOylation of SERCA2a is enhanced, then cardiac function and contractility are improved, but the complexity of therapeutic agents increases
Solution Approach 1:
The patent changes the chemical parameters of small molecule compounds to optimize their ability to activate SUMO1. By modifying molecular structure, lipophilicity, and binding affinity of the compounds, the invention achieves effective SUMOylation activation with simple oral administration, rather than complex gene therapy protocols. This parameter optimization allows simple agents to achieve complex biological effects.
3Ease of operation
If small molecules are developed to increase SERCA2a SUMOylation, then treatment simplicity is improved, but manufacturing precision and compound optimization become more challenging
Solution Approach 1:
The patent employs a screening approach that tests numerous compounds at varying concentrations to identify those with sufficient SUMO1 activation activity. Rather than optimizing a single compound to perfection, the invention accepts that some compounds will require higher doses or less precise manufacturing, trading off manufacturing precision for the benefit of simpler administration and faster development timelines.
Data Source
AI summary
Provided are SUMO activators, which can enhance SUMOylation of SERCA2a, which are useful in the treatment of heart failure, cardiovascular diseases, cancer, neurodegenerative disorders, viral infection, bacterial infection, liver disease, inflammation, and other diseases.